Introduction
Caesarean section (CS) scar defects can be identifi ed using high resolution transvaginal ultrasound (TVS) and are present in up to 19% of women post CS 1 . Th e ultrasound features include myometrial thinning with a demonstrable defect in the myometrium noted on TVS or scar dehiscence at the level of the lower anterior myometrium in women who have undergone previous CS 2 . Detectable myometrial thinning is defi ned as defi cient scar, dehiscence is partial separation of the scar and rupture is separation of the majority of the scar.
Primary caesarean delivery carries potential risks in subsequent pregnancies 3, 4 . Complications associated with CS, although rare, are increasing in frequency and include uterine rupture or scar dehiscence during the ante-or intra-partum period, ectopic pregnancy implantation known as caesarean section scar Jane Fonda MEd, BAppSc, DMU, AMS, Fellow ASUM
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Correspondence to author via Email Jane Fonda jfonda888@ yahoo.co.uk ectopic pregnancy (CSEP), placenta accreta, placenta increta or placenta percreta 5 . Clinical history, which may raise the index of suspicion for CS defects in the non-pregnant woman, is non-specific and may include symptoms of chronic pelvic pain, dysmenorrhoea or postmenstrual spotting 6 . High resolution TVS provides a valuable tool for the investigation of infertility. Th e lower uterus and cervix can be examined with manipulation of the probe into the anterior or posterior fornix for the anteverted (Fig. 1) or retroverted ( Fig. 2) uterus. When the uterus is located in the axial plane the lower uterus can still be examined by using a systematic approach to the area. TVS provides high defi nition of the tissue layers, which is not seen transabdominally and therefore plays an integral role in any gynaecological examination.
Previous CS scars can be examined for their
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Management of the dehiscence within the CS can be expectant or surgical, however it is important to remember that there are no data to support the routine repair of CS defect noted incidentally on TVS 5, 7, 8 . When pregnancy occurs in women who have had a previous CS, prior knowledge of the integrity of the CS is not a predictor of either future delivery mode or delivery outcome. Ultrasound studies of the uterus can demonstrate the intact CS scar, which appears as an echogenic line through the lower anterior myometrium (Figs. 4, 5, 6 ).
Carefully studying the scar in both longitudinal and transverse planes will demonstrate dehiscence and its location.
When the uterus is retroverted the probe can be maneuvered into the posterior fornix to image the uterus well. Th is allows the beam to intersect the scar at 90 degrees and will demonstrate the scar well (Figs. 2, 8, 9 , 10).
In our fertility population, defects within the CS scar were more clearly delineated in women being stimulated for assisted conception; this was associated with an increase in intrauterine/cervical secretions which in turn provided a natural contrast fl uid.
Pitfalls include not focusing on the area, not being able to position the probe in the anterior or posterior fornix (Fig. 11) for the optimal view of the region in question or the lack of intra-uterine/cervical fl uid to act as a negative contrast agent to demonstrate the CS defect.
In conclusion, the detection of CS defects using TVS in women undergoing fertility investigations is well accepted. What is not fully understood is whether such CS defects do indeed result in demonstrable sequelae including CSEPs 5 . Is the history of CS itself a risk factor for sequelae or does a woman need to have a demonstrable CS defect noted on scan? Is the rate of complications the same in women with a CS scar defect compared to those women who have no demonstrable CS scar defect? These questions are still unanswered and future studies are required to guide the ultrasound community as to whether we should be routinely commenting on an incidental finding of a CS defect. 
